Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Wegovy (semaglutide) is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight. It is also indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity and in adults with overweight in the presence of at least one weight-related comorbid condition.
• This summary is based on the review of 20 systematic review(s)/meta-analysis(es). ^[1-20]
• Weight Loss: Semaglutide was associated with significant weight reduction across various studies, including a weight loss of -5.88 kg/m² (95% CI: -6.99 to -4.77), -11.51 kg (95% CI: -12.83 to -10.21), and -10.09% (95% CI: -11.84 to -8.33).
• BMI Reduction: Semaglutide significantly reduced BMI, with a reduction of -2.373 kg/m² (95% CI: -2.821 to -1.924), indicating a prominent anti-obesity effect.
• Waist Circumference: Semaglutide led to a reduction in waist circumference, with reductions such as -7.21 cm (95% CI: -8.87 to -5.56) and -8.28 cm (95% CI: -9.51 to -7.04).
• Cardiometabolic Benefits: Semaglutide was effective in improving cardiometabolic profiles, including glycemic control and cardiovascular risk factors.
• Higher incidence of gastrointestinal adverse events, such as nausea and vomiting, was noted with semaglutide compared to placebo, with specific studies consistently reporting these outcomes.
• Semaglutide 2.4 mg was associated with a high incidence of overall adverse events, including hypoglycemia.
• In adolescents, serious adverse events occurred in about 1 in 100 participants.
• Semaglutide was effective in reducing BMI in adolescents with obesity, in weight loss and improving cardiometabolic profiles in non-diabetic obese adults, in both men and women with distinctive results in subgroups of women, and showed potential cardiovascular benefits in high-risk cardiovascular populations, although further studies are required.